Efficacy and safety of Itraconazole injections and capsules in deep mycosis uncontrolled multicenter open-label trial

• Kohno Shigeru

  Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences

• Yamaguchi Hideyo

  Teikyo University Institute of Medical Mycology

• Mori Takeshi

  Department of Hematology, Juntendo University School of Medicine

• Hirai Hisamaru

  University of Tokyo Hospital, Department of Cell Therapy and Transplantation Medicine

• Oritsu Masaru

  Department of Respiratory Medicine, Japanese Red Cross Medical Center

• Niki Yoshihito

  Department of Respiratory Medicine, Kurashiki First Hospital

• Yoshida Minoru

  Fourth Department of Internal Medicine, Teikyo University School of Medicine University Hospital

• Maesaki Shigefumi

  First Department of Internal Medicine, Saitama Medical University Hospital

• Hiraoka Akira

  Fifth Department of Internal Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases

• Kurashima Atsuyuki

  Division of Clinical Research, National Sanatorium (currently National Hospital Organization), Tokyo Hospital

Bibliographic Information

Other Title

• 深在性真菌症患者に対するitraconazole注射薬およびカプセル薬順次投与の有効性
• Itraconazole-Deep Mycosis Research Group
• Itraconazole深在性真菌症研究班

Abstract

We investigated the efficacy and safety of Itraconazole (ITCZ) in patients with deep mycosis, evaluating intravenous injection of ITCZ (200 mg) for 2 weeks (twice a day for the first two days, then once a day for the remaining 12 days) prior to the oral administration of ITCZ capsules (200 mg) twice a day.<BR>Total efficacy was 67.7%(21/31 cases). The efficacy in aspergillosis patients was 57.9%(11/19 cases), 71.4%(5/7) in candidiasis patients, and 100%(5/5) in cryptococcosis patients. No difference was seen in the incidence of adverse events in injection and capsule administration, and most observed adverse events of ITCZ were already known.<BR>ITCZ plasma trough concentration after two days of injection (200 mg twice a day) reached a level (811.3±316.0 ng/mL, Mean ± S. D., n=42) efficient in treating conditions caused by primary underlying mycoses (Aspergillus, Candida, Cryptococcus), and high plasma was maintained continuously through administration of ITCZ capsules.<BR>ITCZ injection reaches efficient plasma concentration rapidly compared to ITCZ capsules. ITCZ injection is effective for serious and acute conditions but the approved maximum dose of 200 mg/day for ITCZ capsules is not effective in treating deep mycosis.<BR>Plasma concentration reached by ITCZ injection is continuously maintained through the administration of ITCZ capsules (200 mg, twice a day). We concluded that the first 2 weeks of injection prior to oral administration is effective in treating deep mycosis.

Journal

• Japanese Journal of Chemotherapy

  Japanese Journal of Chemotherapy 54 (Supplement1), 32-47, 2006

  Japanese Society of Chemotherapy

Keywords

• itraconazole
• injection
• aspergillosis
• candidiasis
• cryptococcosis

Details

• CRID: 1390282681267280384
• NII Article ID: 10018303691
• NII Article ID: 130004298314
• NII Book ID: AN10472127
• DOI: 10.11250/chemotherapy1995.54.supplement1_32
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/2007049431
• Text Lang: ja
• Data Source:
  • JaLC
  • CiNii Articles
• Abstract License Flag: Disallowed